Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP)

Sponsor
Escala Medical LTD (Industry)
Overall Status
Completed
CT.gov ID
NCT03991455
Collaborator
(none)
17
1
1
30.2
0.6

Study Details

Study Description

Brief Summary

The aim of this study is to further evaluate this minimally invasive SSLF technique with respect to safety, clinical effectiveness, and patient satisfaction. The procedure will be performed in women electing to undergo surgical repair of their prolapse who wish to preserve their uterus, and will be evaluated using standardized measures and questionnaires.

Condition or Disease Intervention/Treatment Phase
  • Device: Apyx device
N/A

Detailed Description

This study will evaluate sacrospinous ligament fixation using an incision-free technique - a technique that was developed with the goal of offering a technically simple, safe, and effective alternative to surgical prolapse repair procedures. When compared to previously reported SSLF methods, this technique has undergone novel modifications with the intent of maximizing efficacy and minimizing invasiveness. First, each sacrospinous ligament is approached trans-vaginally using a small diameter, low profile needle as the delivery platform for the anchoring unit. Secondly, the suspension is bilateral, thus maintaining vaginal length and width without deviation or narrowing of the vagina as might occur with a traditional (unilateral) sacrospinous repair. And third, using bio-degradable sutures and a securing element that stabilizes the fixation as opposed to performing an incision in the vaginal wall for suturing enables an incision-free procedure leaving the vagina free of any device after a period of several weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
17 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP)
Actual Study Start Date :
Oct 25, 2019
Actual Primary Completion Date :
May 1, 2022
Actual Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Apyx device treatment

The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system. Using the device, SSLF can be performed transvaginally without the need for any incisions or blind dissections and without the requirement of heavy anesthesia.

Device: Apyx device
The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.

Outcome Measures

Primary Outcome Measures

  1. Change in PFDI-20 Prolapse Subscale (POPDI-6) score [6 months]

    Pelvic Floor Disability Index (PFDI-20) includes 20 questions are rated from 0 to 4, with 0 is no present of distress and 4 is the highest of symptom scale. Pelvic Floor Disability Index distress index is a subscale of the first 6 questions of the above scale

Secondary Outcome Measures

  1. Objective success rate [6 months]

    POP-Q points Ba less than -1 and C less than -½ TVL

  2. Change in PFDI-20 [at baseline 3 months, 6 months, and 12 months compared to preoperative]

    Pelvic Floor Disability Index (PFDI-20) includes 20 questions are rated from 0 to 4, with 0 is no present of distress and 4 is the highest of symptom scale

  3. Change in PISQ-12 scores [at baseline 3 months, 6 months, and 12 months compared to preoperative]

    The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire -12 (PISQ-12) includes question for estimation of sexual function for women with POP urinary incontinence and or fecal incontinence

  4. PGI-I [3 months, 6 months, and 12 months]

    Patient Global Impression of Improvement include one question which describes how the patient evaluates the post surgery improvement with a scale of 1 to 7. 1 is very much better and 7 is very much worse

  5. Unanticipated Device-related Serious Adverse Event rate [at intervals of 2 weeks, 3 months, 6 months, and 12 months]

    Unanticipated Device-related Serious Adverse Event rate

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Women with prolapse electing to undergo reconstructive vaginal surgery for primary uterovaginal prolapse, who wish to enroll in this trial of an incision-free prolapse repair technique, after being familiarized with the suspected benefits and risks of the procedure.

  • Ages 18-90 years old

  • POP-Q Stage 2 or greater with an apical support defect, also defined as uterovaginal prolapse

  • Desire of uterine preservation

  • Patient is willing to return for follow-up evaluation and questionnaire completion at 3 months, 6 months, and 12 months, in addition to routine postoperative standard of care.

  • English fluency

Exclusion Criteria:
  • Previous vaginal, abdominal, or laparoscopic repair for pelvic organ prolapse

  • Prior hysterectomy

  • Known allergy to Nitinol / Stainless Steel / Polydioxanone.

  • Suspected uterine pathology, including malignancy.

  • History of chronic pelvic pain, interstitial cystitis or fibromyalgia.

  • Women diagnosed with symptomatic uterine fibroids, cervical elongation or hypertrophy, abnormal uterine or vaginal bleeding.

  • History of Pelvic Inflammatory Disease (PID)

  • Prior pelvic radiation therapy or malignancy.

  • Diagnosis of reproductive tract anomalies.

  • Pregnant or lactating women.

  • Participation in another trial

  • Inability to provide informed consent for study enrollment

  • PI's subjective assessment that study procedure will not plausibly correct patient pelvic organ prolapse symptoms due to anatomic considerations

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rambam Medical Center Haifa Israel 3109601

Sponsors and Collaborators

  • Escala Medical LTD

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Escala Medical LTD
ClinicalTrials.gov Identifier:
NCT03991455
Other Study ID Numbers:
  • 1806019328
First Posted:
Jun 19, 2019
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022